Header image  
biomarkers for Alzheimer’s disease  
line decor
line decor


Welcome to the website of the EDAR study. The EDAR study is a European collaborative study, which aims to develop and validate new biomarkers for Alzheimer’s disease.

Central in the project is the development of an assay for the measurement of beta amyloid oligomers in cerebrospinal fluid and plasma. Beta amyloid oligomers have been recognized as a key pathogen in AD only recently. Due to their low concentration, they cannot be measured with regular techniques. In the present study, ultra-sensitive assays will be developed in order to measure oligomers in vivo.

In order to validate the assay for beta amyloid oligomers, cerebrospinal fluid and plasma will be repeatedly collected in subjects with Alzheimer’s disease, other types of dementia, Mild Cognitive Impairment, and control subjects.

For a more detailed description see ‘Outline’. A summary in non-technical terms is given at ‘Summary’.




The Project
The EDAR project has been funded by the European Commission as part of the 6th framework programme in the theme ‘Life sciences, genomics and biotechnology for Health’, and thematic area ‘Application of knowledge and technologies in the field of genomics and biotechnology for health’.

EDAR is the acronym for Beta amyloid oligomers in the early diagnosis of AD and as marker for treatment response.